Ellie Leick

Articles

CAR T-Cell Therapy Continues to Generate Positive Results in Hematologic Cancers

January 29th 2020

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

Targeted Therapy Shifts AML Paradigm, But More Work Lies Ahead

January 28th 2020

Prapti Patel, MD, discusses available and emerging treatment options for patients with acute myeloid leukemia.

Surgical Advances Improve QoL in Gynecologic Cancers

January 24th 2020

Mira Hellmann, MD, discusses surgical and systemic advancements in the field of gynecologic oncology.

Updated Data Unveiled With Emerging Treatments in Myeloma

January 23rd 2020

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

Experts Highlight Benefits and Challenges With Biosimilars in Breast Cancer

January 22nd 2020

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Neratinib Regimens Elicit CNS Responses in HER2+ Breast Cancer

January 15th 2020

Nancy U. Lin, MD, discusses research focusing on CNS penetration in HER2-positive metastatic breast cancer.

Treatment Decisions Shifting in HER2+ Breast Cancer

January 14th 2020

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer

January 14th 2020

Hope S. Rugo, MD, FASCO, discusses the updated findings of the SOPHIA trial in HER2-positive metastatic breast cancer.

Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer

January 14th 2020

Rashmi K. Murthy, MD, MBE, discusses the findings of the HER2CLIMB trial in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer

January 13th 2020

Martine J. Piccart, MD, PhD, discusses the 6-year follow-up of the APHINITY trial and its impact on the breast cancer field.

Immunotherapy Combos Emerge as Standard Frontline Treatment in Advanced RCC

January 10th 2020

David F. McDermott, MD, discusses developments in the frontline setting for the treatment of patients with advanced renal cell carcinoma.

Targeted Therapy Approvals Spur Increased Biomarker Research in AML

January 9th 2020

Alice Mims, MD, discusses biomarker research and therapeutic developments in acute myeloid leukemia.

Woyach Highlights Progress and Next Steps in CLL Paradigm

January 8th 2020

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

Expert Highlights Research Developments Across the Spectrum in Multiple Myeloma

January 7th 2020

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

Single-Agent and Combo Approvals Lead to Personalized Approach in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, highlights ongoing advances made in the treatment of patients with metastatic renal cell carcinoma.

Challenges Remain With Pancreatic Cancer Staging

January 6th 2020

Afonso Ribeiro, MD, discusses imaging modalities as well as challenges and future goals for the pancreatic cancer paradigm.

Liquid Biopsies Are Link to Increasing Molecular Testing in Lung Cancer

January 2nd 2020

Nathan Pennell, MD, PhD, discusses the emerging widespread role of liquid biopsies in lung cancer and how to best utilize the approach in clinical practice.

AML Research Efforts in Full Swing After Decades of Stagnation

December 28th 2019

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Biosimilars Poised to Drive Down Treatment Costs in Oncology

December 23rd 2019

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

ADP-A2M4 Shows Early Promising Clinical Activity in Synovial Sarcoma

December 20th 2019

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.